Premium
Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry
Author(s) -
O'Brien Seamus
Publication year - 2015
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.12401
Subject(s) - reimbursement , pharmaceutical industry , antibiotics , intensive care medicine , business , psychological intervention , risk analysis (engineering) , medicine , antibiotic resistance , pharmacology , economics , health care , economic growth , nursing , microbiology and biotechnology , biology
The rise of antibiotic resistance is leading to clinicians being increasingly faced with clinical failure due to the lack of effective and safe treatment options. New antibiotics are needed now for current multi‐drug resistant infections but also in preparation for emerging and anticipated threats. There are significant challenges for the pharmaceutical industry to discover and develop new antibiotics including a business model that balances reasonable reimbursement with appropriate use. This summary reviews the key challenges and collaborative interventions that may contribute to addressing a societal problem.